|
Receptors, Purinergic P2X
|
D12.776.543.750.720.700.720.500 |
|
|
Lycium
|
B01.650.940.800.575.912.250.908.500.310 |
|
|
Fish Venoms
|
D23.946.833.370 |
|
|
Chemokine CXCL16
|
D23.529.374.200.120.075 |
|
|
cdc42 GTP-Binding Protein
|
D08.811.277.040.330.300.400.700.050 |
|
|
Interrupted Time Series Analysis
|
D065186 |
[A study that uses observations at multiple time points before and after an intervention (the "interruption"), in an attempt to detect whether the intervention has had an effect significantly greater than any underlying trend over time.
] |
|
Controlled Before-After Studies
|
D065187 |
[A study in which observations are made before and after an intervention, both in a group that receives the intervention and in a control group that does not.
] |
|
Adenovirus E1B Proteins
|
D12.776.930.110 |
|
|
Viral Replication Compartments
|
A11.284.420.390.500 |
|
|
Inclusion Bodies, Viral
|
A11.284.420.390 |
|
|
Viscosupplementation
|
E02.319.267.530.380.500 |
|
|
Injections, Intra-Articular
|
E02.319.267.530.380 |
|
|
Muscular Dystrophy, Emery-Dreifuss
|
C05.651.534.500.350 |
|
|
Fraud
|
I01.198.240.300 |
|
|
Lingual Thyroid
|
C19.874.689.500 |
|
|
Thyroid Dysgenesis
|
C19.874.689 |
|
|
Topography, Medical
|
H01.277.500.097.500 |
|
|
Geography, Medical
|
H01.277.500.097 |
|
|
Cerebral Veins
|
A07.015.908.155 |
|
|
Estrogen Receptor Antagonists
|
D065171 |
[Compounds and drugs that bind to and block or inhibit the activation of ESTROGEN RECEPTORS.
] |
